Publication
Title
Effect of statin therapy on the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with hyperlipidemia : a proof-of-concept observational study
Author
Abstract
Purpose: Statins are commonly used in patients with hypercholesterolemia to lower their cholesterol levels and to reduce their cardiovascular risk. There is also considerable evidence that statins possess a range of cholesterol-independent effects, including profibrinolytic properties. This pilot study aimed to explore the influence of statins on procarboxypeptidase U (proCPU) biology and to search for possible effects and associations that can be followed up in a larger study. Methods: Blood was collected from 16 patients with hyperlipidemia, before and after 3 months of statin therapy (simvastatin 20 mg or atorvastatin 20 mg). Fifteen age-matched normolipemic persons served as control subjects. Lipid parameters and markers of inflammation and fibrinolysis (proCPU levels and clot lysis times) were determined in all samples. Findings: Mean (SD) proCPU levels were significantly higher in patients with hypercholesterolemia compared to control subjects (1186 [189] U/L vs 1061 [60] U/L). Treatment of these patients with a statin led to a significant average decrease of 11.6% in proCPU levels and brought the proCPU concentrations to the same level as in the control subjects. On a functional level, enhancement in plasma fibrinolytic potential was observed in the statin group, with the largest improvement in fibrinolysis seen in patients with the highest baseline proCPU levels and largest proCPU decrease upon statin treatment. (C) 2021 Elsevier Inc.
Language
English
Source (journal)
Clinical therapeutics. - Princeton, N.J.
Publication
Princeton, N.J. : 2021
ISSN
0149-2918
DOI
10.1016/J.CLINTHERA.2021.03.011
Volume/pages
43 :5 (2021) , p. 908-916
ISI
000686776700016
Pubmed ID
33910760
Full text (Publisher's DOI)
Full text (open access)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Project info
Carboxypeptidase U - a new drug target for the improvement of treatment in acute ischemic stroke.
Infla-Med: Fundamental and translational research into targets for the treatment of inflammatory diseases.
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 05.10.2021
Last edited 02.10.2024
To cite this reference